Combination therapy for the treatment of autoimmune diseases

Abstract

The present invention pertains to compounds and their combination for use in the prevention or therapy of a subject suffering from an autoimmune disease such as diabetes type 1. Provided are antagonists of T-cells that are used in combination with antagonists of the cytokine CXCL10, sequentially or concomitantly, in a subject suffering from an autoimmune disease, in particular diabetes type 1.

1 - 15 . (canceled) 
     
     
         16 . A method for the prevention or treatment of an autoimmune disease in a subject, wherein the method comprises an administration of a T-cell-antagonist to said subject, and wherein the subject is additionally treated with a C-X-C motif chemokine 10 (CXCL10)-antagonist. 
     
     
         17 . The method according to  claim 16 , wherein said prevention or treatment comprises the administration of said T-cell-antagonist to a subject suffering from an autoimmune disease, and wherein said subject received, receives or will receive a treatment with a CXCL10-antagonist. 
     
     
         18 . The method according to  claim 16 , wherein said prevention or treatment comprises the concomitant or sequential administration of said T-cell-antagonist and said CXCL10-antagonist. 
     
     
         19 . A method for the prevention or treatment of an autoimmune disease in a subject, wherein the method comprises an administration of a C-X-C motif chemokine 10 (CXCL10)-antagonist to the subject, and wherein said subject is additionally treated with a T-cell-antagonist. 
     
     
         20 . The method according to  claim 19 , wherein in said prevention or treatment comprises the administration of said CXCL10-antagonist to a subject suffering from an autoimmune disease, and wherein said subject received, receives or will receive a treatment with a T-cell-antagonist. 
     
     
         21 . The method according to  claim 19 , wherein said prevention or treatment comprises the concomitant or sequential administration of said CXCL10-antagonist and said T-cell-antagonist. 
     
     
         22 . A method for the prevention or treatment of an autoimmune disease in a subject, wherein the method comprises a concomitant or sequential administration of a combination comprising (i) a T-cell-antagonist and (ii) a C-X-C motif chemokine 10 (CXCL10)-antagonist. 
     
     
         23 . The method according to  claim 22 , wherein antagonists (i) and (ii) are combined by sequential or concomitant administration to a subject during said prevention or treatment. 
     
     
         24 . The method according to  claim 16 , wherein said antagonists are selected from the group of compounds consisting of inhibitory RNA, inhibitory antibody, and small molecule. 
     
     
         25 . The method according to  claim 16 , wherein the autoimmune disease is diabetes or type 1 diabetes. 
     
     
         26 . The method according to  claim 16  wherein said T-cell-antagonist is a CD3-antagonist. 
     
     
         27 . The method according to  claim 16 , wherein at least one additional therapeutic agent effective against said autoimmune disease is administered to said subject. 
     
     
         28 . The method according to  claim 27 , wherein said at least one additional therapeutic agent is selected from the group of islet-cell-antigen, rapamycin and a probiotic. 
     
     
         29 . A method for the prevention or treatment of an autoimmune disease in a subject, the method comprising the steps of administering to said subject a therapeutically effective amount of a T-cell-antagonist and a CXCL10-antagonist. 
     
     
         30 . The method according to  claim 29 , wherein said T-cell-antagonist and said CXCL10-antagonist are administered to said subject sequentially, or concomitantly. 
     
     
         31 . The method according to  claim 29 , wherein said autoimmune disease is diabetes. 
     
     
         32 . The method according to  claim 29 , wherein said antagonist is selected from the group of compounds consisting of inhibitory RNA, inhibitory antibody, and small molecule. 
     
     
         33 . The method according to  claim 29 , wherein said T-cell-antagonist is a CD3-antagonist. 
     
     
         34 . The method according to  claim 29 , wherein at least one additional therapeutic agent effective against said autoimmune disease is administered to said patient. 
     
     
         35 . The method according to  claim 34 , wherein said at least one additional therapeutic agent is selected from the group of islet-cell-antigen, rapamycin and a probiotic, such as  Lactococcus lactis.    
     
     
         36 . The method according to  claim 29 , wherein said subject is a mammal. 
     
     
         37 . The method according to  claim 29 , wherein said subject is suffering from type 1 diabetes and wherein said subject received a pancreas and/or islet transplantation.